Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Une raison de plus pour déprescrire les IPP ?

Fierz Y.

Rev Med Suisse. 2019 Sep 11;15(662):1640. French. No abstract available.

PMID:
31508920
2.

[2018 scientific breakthroughs in ambulatory general internal medicine].

Gouveia A, Pasche O, Auer S, Chenal R, De Alencastro L, Fierz Y, Gray R, Koehli L, Monney C, Selby K, Bodenmann P.

Rev Med Suisse. 2019 Jan 17;15(634):129-133. French.

PMID:
30657262
3.

Initiation d’un bronchodilatateur à longue durée d’action et risque cardiovasculaire.

Fierz Y.

Rev Med Suisse. 2018 Mar 21;14(599):652. French. No abstract available.

PMID:
29561578
4.

[General internal medicine : 2017 scientific breakthroughs in ambulatory care].

Gouveia A, De Alencastro L, Fierz Y, Koehli L, Béguelin A, Pasche O, Selby K, Bodenmann P.

Rev Med Suisse. 2018 Jan 17;14(590):130-134. French.

PMID:
29341525
5.

Une activité physique uniquement le week-end suffit-elle ?

Fierz Y.

Rev Med Suisse. 2017 Mar 8;13(553):580. French. No abstract available.

PMID:
28718595
6.

Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.

Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti Bertrand P.

Eur J Clin Nutr. 2014 Apr;68(4):531-3. doi: 10.1038/ejcn.2014.20. Epub 2014 Feb 26.

PMID:
24569537
7.

Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.

Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, Leroith D.

Breast Cancer Res. 2012 Jan 7;14(1):R8.

8.

Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.

Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.

Oncogene. 2012 Jul 5;31(27):3213-22. doi: 10.1038/onc.2011.495. Epub 2011 Oct 31.

9.

The GH/IGF-1 axis in growth and development: new insights derived from animal models.

Cannata D, Vijayakumar A, Fierz Y, LeRoith D.

Adv Pediatr. 2010;57(1):331-51. doi: 10.1016/j.yapd.2010.09.003. No abstract available.

PMID:
21056746
10.

The pathway from diabetes and obesity to cancer, on the route to targeted therapy.

Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D.

Endocr Pract. 2010 Sep-Oct;16(5):864-73. doi: 10.4158/EP10098.RA. Review.

PMID:
20841312
11.

Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.

Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D.

Endocr Relat Cancer. 2010 Oct 5;17(4):941-51. doi: 10.1677/ERC-10-0091. Print 2010 Dec.

12.

Type 2 diabetes and cancer: what is the connection?

Cannata D, Fierz Y, Vijayakumar A, LeRoith D.

Mt Sinai J Med. 2010 Mar-Apr;77(2):197-213. doi: 10.1002/msj.20167. Review.

PMID:
20309918
13.

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D.

Cancer Res. 2010 Jan 15;70(2):741-51. doi: 10.1158/0008-5472.CAN-09-2141. Epub 2010 Jan 12.

14.

Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.

Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D.

Diabetes. 2010 Mar;59(3):686-93. doi: 10.2337/db09-1291. Epub 2009 Dec 3.

15.

Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation.

Novosyadlyy R, Vijayakumar A, Lann D, Fierz Y, Kurshan N, LeRoith D.

Oncogene. 2009 Oct 1;28(39):3477-86. doi: 10.1038/onc.2009.209. Epub 2009 Jul 20.

Supplemental Content

Support Center